<DOC>
	<DOCNO>NCT00023842</DOCNO>
	<brief_summary>RATIONALE : Biological therapy BCG use different way stimulate immune system stop tumor cell grow . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy biological therapy may kill tumor cell . It yet know BCG effective without mitomycin . PURPOSE : Randomized phase II trial compare effectiveness BCG plus mitomycin BCG alone treat patient bladder cancer .</brief_summary>
	<brief_title>BCG With Without Mitomycin Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare complete response rate patient carcinoma situ bladder treat adjuvant intravesical BCG without intravesical mitomycin follow transurethral resection . - Compare disease-free interval type recurrence complete response patient treat regimen . - Compare side effect regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients randomize one two treatment arm . Arm I : - Induction therapy : Patients receive intravesical mitomycin 1 hour weekly week 1-6 intravesical BCG weekly week 7-12 . Patients visible lesion disease recurrence progression undergo transurethral resection ( TUR ) week 16-18 receive one additional course intravesical therapy . - Maintenance therapy : Patients complete response either course induction therapy proceed maintenance therapy comprise intravesical mitomycin week 1 intravesical BCG weekly week 2 3 . Maintenance therapy repeat every 6 month year 3 . Arm II : - Induction therapy : Patients receive intravesical BCG weekly week 1-6 10-12 . Patients visible lesion disease recurrence progression undergo transurethral resection ( TUR ) week 16-18 receive one additional course intravesical therapy . - Maintenance therapy : Patients complete response either course induction therapy receive maintenance therapy comprise intravesical BCG weekly week 1-3 . Maintenance therapy repeat every 6 month year 3 . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 84-126 patient ( 42-63 per treatment arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma situ ( CIS ) bladder urinary cytology Primary CIS ( prior history CIS , papillary , solid transitional cell carcinoma [ TCC ] bladder concurrent papillary solid TCC ) OR Secondary CIS ( detect complete resection superficial Ta/T1 TCC bladder ) OR Concurrent CIS ( presence superficial primary recurrent Ta/T1 TCC bladder ) No 28 day since prior transurethral resection ( TUR ) visible lesion No muscle involvement No prior concurrent upper urinary tract tumor No urethral stricture would prevent endoscopic procedure repeat catheterization No upper urinary tract disease ( e.g. , vesicoureteral reflux massive stone ) would make multiple transurethral procedure risky PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing No active tuberculosis ( highly positive skin test allow active disease ) No disease would preclude general anesthesia No active intractable uncontrollable infection No prior concurrent malignancy except cure basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior BCG Chemotherapy : More 3 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pelvis Surgery : See Disease Characteristics Other : More 3 month since prior intravesical cytostatic agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>